Recent Updates
Recently added Catalysts
JANX Positive Sentiment

Janux Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights

Thursday, November 5, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Janux Therapeutics reported its Q3 2026 financial results, highlighting the dosing of the first patient in its Phase 1 study of JANX013 combined with JANX007. The company emphasized its ongoing execution across its clinical portfolio, indicating progress in its development efforts.

Market Sentiment Analysis

POSITIVE FACTORS

  • First patient dosed in Phase 1 study of JANX013.
  • Continued execution across clinical portfolio.
  • Strong financial results reported for Q3 2026.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+10%
120-day peak, hindsight
Typical move
7.9%
average across 5 past catalysts
Lead asset
JANX007
Phase 1 · Prostate Cancer

Full Press Release Details

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today reported financial results for the quarter ended September 30, 2026, and provided a business update. “During the third quarter, we continued to execute across our clinical portfolio, including dosing the first patient in the Phase 1 study of JANX013 in combination with JANX007,” said David Campbell, Ph.D., President a

Frequently Asked Questions

What were the key highlights from Janux's Q3 2026 report?

Janux reported the dosing of the first patient in its Phase 1 study of JANX013.

What is JANX013?

JANX013 is an investigational immunotherapy being studied in combination with JANX007.

When did Janux report its Q3 2026 financial results?

Janux reported its financial results for the quarter ended September 30, 2026.

Who is the President of Janux Therapeutics?

David Campbell, Ph.D., is the President of Janux Therapeutics.

ShareAdd on Google
Tags: JANX Janux Therapeutics Phase 1 study immunotherapies financial results
Last updated: Nov 5, 2026

Biotech snapshot

Cash runway
$971M liquidity · $0M/mo burn
Low dilution risk
Lead asset
JANX007Phase 1
Prostate Cancer →

Catalyst track record

+10%
best trade around JANX's most recent catalyst

Peak hindsight return over a 120-day window, across 5 tracked FDA/PDUFA catalysts for JANX.

See every catalyst's timing & PoA →